Canada - English - Health Canada

novo nordisk a/s - insulin injection human biosynthetic; insulin isophane human biosynthetic - suspension - 30unit; 70unit - insulin injection human biosynthetic 30unit; insulin isophane human biosynthetic 70unit - insulins

United States - English - NLM (National Library of Medicine)

pfizer inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - kit - 1 mg - exubera is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. exubera has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. in patients with type 1 diabetes, exubera should be used in regimens that include a longer-acting insulin. in patients with type 2 diabetes, exubera can be used as monotherapy or in combination with oral agents or longer-acting insulins. exubera is contraindicated in patients hypersensitive to exubera or one of its excipients. exubera is contraindicated in patients who smoke or who have discontinued smoking less than 6 months prior to starting exubera therapy. if a patient starts or resumes smoking, exubera must be discontinued immediately due to the increased risk of hypoglycemia, and an alternative treatment must be utilized (see clinical pharmacology, special populations, smoking). the safety and efficacy of exube

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: zinc; dibasic sodium phosphate dihydrate; protamine sulfate; metacresol; sodium chloride; sodium hydroxide; glycerol; phenol; hydrochloric acid; water for injections - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; sodium chloride; sodium hydroxide; water for injections; hydrochloric acid; zinc; metacresol; dibasic sodium phosphate dihydrate; glycerol - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; zinc; dibasic sodium phosphate dihydrate; sodium hydroxide; glycerol; metacresol; sodium chloride; water for injections; hydrochloric acid - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: water for injections; metacresol; glycerol; sodium chloride; dibasic sodium phosphate dihydrate; hydrochloric acid; sodium hydroxide; zinc; phenol - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - insulin glulisine, quantity: 3.49 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; metacresol; polysorbate 20; trometamol; hydrochloric acid; sodium hydroxide - apidra is indicated for the treatment of type 1 and type 2 diabetes mellitus in adults and children of 4 years or above who require insulin for the control of hyperglycaemia.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - insulin isophane porcine; insulin soluble porcine - suspension for injection - 70unit/1ml ; 30unit/1ml

Philippines - English - FDA (Food And Drug Administration)

scigen ltd.; importer: metro drug inc.; distributor: metro drug inc. - insulin human (rdna) - suspension for injection (sc) - 30% soluble insulin + 70% isophane insulin 100 iu/ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

biocon sdn bhd - insulin human -